Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The DACH moiety also prevents cross-resistance with cisplatin and carboplatin.
Although oxaliplatin has been investigated as a monotherapy, it is typically administered in combination with fluorouracil and leucovorin, known as the FOLFOX regimen, for the treatment of colorectal cancer. This is an effective combination treatment both as a first-line treatment and in patients refractory to an initial fluorouracil and leucovorin combination. Ongoing trials have also shown promising results for oxaliplatin use in nonHodgkin’s lymphoma, breast cancer, mesothelioma, and non-small cell lung cancer.
Oxaliplatin was approved by the FDA on January 9, 2004 and is currently marketed by Sanofi-Aventis under the trademark Eloxatin®.
Oxaliplatin, in combination with infusional fluorouracil and leucovorin, is indicated for the treatment of advanced colorectal cancer and adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor.
UCLA Ronald Reagan Med Ctr, Santa Monica, California, United States
Smillow Cancer Hosp, New Haven, Connecticut, United States
Regions Hospital, Saint Louis Park, Minnesota, United States
Baylor College of Medicine, Houston, Texas, United States
Baylor College of Medicine Medical Center - McNair Campus, Houston, Texas, United States
Baylor St. Luke's Medical Center, Houston, Texas, United States
Northwestern Medicine Grayslake Outpatient Center, Grayslake, Illinois, United States
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan, United States
Corewell Health Dearborn Hospital, Dearborn, Michigan, United States
Corewell Health Farmington Hills Hospital, Farmington Hills, Michigan, United States
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
CHU de GRENOBLE ALPES, Grenoble, Alpes, France
CHU de BORDEAUX, Bordeaux, France
CHRU Lille, Lille, France
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Brigham and Women's Hospital, Boston, Massachusetts, United States
Shanghai General Hospital, Shanghai, China
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.